<DOC>
	<DOCNO>NCT01595048</DOCNO>
	<brief_summary>This randomized phase II/III trial study well combination chemotherapy without rituximab work treat young patient stage III-IV non-Hodgkin lymphoma B-cell acute leukemia . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Monoclonal antibody , rituximab , may block cancer growth different way target certain cell . It yet know whether combination chemotherapy together rituximab effective treating patient non-Hodgkin lymphoma B-cell acute leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Rituximab Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma B-Cell Acute Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . For patient advanced stage B-cell non-Hodgkin lymphoma ( NHL ) /Burkitt acute leukemia ( B-AL ) ( stage III lactate dehydrogenase ( LDH ) &gt; twice institutional upper limit adult normal value ( Nx2 ) , stage IV B-AL ) , test whether add 6 injection rituximab standard Lymphome Malin B ( LMB ) chemotherapy regimen , improve event-free survival ( EFS ) compare LMB chemotherapy alone . ( Phase III ) II . For patient primary mediastinal large B-cell lymphoma ( PMLBL ) , evaluate EFS follow treatment regimen dose-adjusted etoposide , prednisone , vincristine sulfate , cyclophosphamide , doxorubicin hydrochloride ( DA-EPOCH ) -rituximab . ( Phase II ) SECONDARY OBJECTIVES : I . To study complete remission ( CR ) rate overall survival ( OS ) . II . To evaluate safety study arm include toxic death , adverse event record use National Cancer Institute ( NCI ) -Common Terminology Criteria ( CTC ) version ( V ) 4 ( non hematological toxicity grade &gt; = 3 , infection grade 3 5 ) , cardiac toxicity ( CTC grade 2-5 evolution leave ventricular ejection fraction leave ventricular shorten fraction ) , number day platelet transfusion , intensive care unit admission number day red cell transfusion , rituximab infusion reaction . III . To study rate patient immunoglobulin ( Ig ) ( G , A , M ) level abnormally low lymphocyte count abnormally low 1 year 5-year follow-up , study need immunoglobulin infusion , level post ( previous re- ) vaccination antibody 1 year . IV . To study long term ( least 5 year ) risk use rituximab plus chemotherapy compare LMB chemotherapy alone child adolescent advanced stage B-NHL/B-AL ( event relate [ certain probable ] therapy ) . ( Phase III ) V. To study long term risk DA-EPOCH-R regimen , especially cardiac risk relate doxorubicin give high dose usual child , infuse 96 hour ( i.e. , evaluation CTC grade 2-5 evolution leave ventricular ejection fraction leave ventricular shorten fraction ) . ( Phase II ) TERTIARY OBJECTIVES : I . To obtain data positron emission tomography ( PET ) -computed tomography ( CT ) scan childhood pediatric B-cell NHL . ( Exploratory ) II . To evaluate potential prognostic value Minimal Disseminated Disease ( MDD ) Minimal Residual disease ( MRD ) correlation outcome . ( Exploratory - Phase III ) III . To perform economic study compare cost-effectiveness ratio 2 therapeutic strategy : LMB chemotherapy versus LMB chemotherapy without rituximab . ( Exploratory - Phase III ) IV . To characterize pharmacokinetics rituximab combination LMB chemotherapy subset patient . ( Exploratory - Phase III ) OUTLINE : Phase II ( patient PMLBL ) : Patients receive rituximab intravenously ( IV ) day 1 ; prednisone orally ( PO ) twice daily ( BID ) IV day day 1-5 ; etoposide IV continuously day 1-4 ; doxorubicin hydrochloride IV continuously day 1-4 ; vincristine sulfate IV continuously day 1-4 ; cyclophosphamide IV day 5 . Patients also receive filgrastim subcutaneously ( SC ) daily ( QD ) begin day 6 blood count recovers . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Phase III : Group I ( pre-phase central nervous system [ CNS ] -negative , cerebral spinal fluid [ CSF ] -negative ) : Patients receive vincristine sulfate IV day 1 ; cyclophosphamide IV 15 minute day 1 ; prednisone PO BID methylprednisolone IV day 1-7 ; methotrexate intrathecally ( IT ) hydrocortisone IT day 1 . Patients randomize 1 2 treatment arm . Arm I ( R-COPADM induction therapy ) : Beginning 8 day later , patient receive rituximab IV day 1 ; vincristine sulfate IV day 1 ; prednisone PO BID methylprednisolone IV day 1-5 ; methotrexate IV 3 hour day 1 ; leucovorin calcium PO every 6 hour day 2-4 ; cyclophosphamide IV 15 minute day 2-4 ; doxorubicin hydrochloride 1 hour day 2 ; methotrexate IT hydrocortisone IT day 2 6 . Treatment repeat every 18-21 day 2 course . Consolidation therapy ( R-COPADM ) : Patients receive rituximab IV day 1 ; methotrexate IV 3 hour day 1 ; leucovorin calcium PO every 6 hour day 2-4 ; cytarabine IV continuously day 2-6 ; methotrexate IT day 2 ; hydrocortisone IT day 2 7 ; cytarabine IT day 7 . Treatment repeat every 21 day 2 course . Arm II ( COPADM induction therapy ) : Beginning 8 day later , patient receive vincristine sulfate , prednisone methylprednisolone , methotrexate , leucovorin calcium , cyclophosphamide , doxorubicin , methotrexate IT , hydrocortisone IT arm I . Treatment repeat every 18-21 day 2 course . Consolidation therapy ( COPADM ) : Patients receive methotrexate IV 3 hour day 1 ; leucovorin calcium PO every 6 hour day 2-4 ; cytarabine IV 12 hour day 2-6 ; methotrexate IT day 2 ; hydrocortisone IT day 2 7 ; cytarabine IT day 7 . Treatment repeat every 21 day 2 course . Group II ( pre-phase B-AL , CNS-negative OR CNS-positive , CSF-negative OR CSF-positive ) : Patients receive vincristine sulfate IV day 1 ; cyclophosphamide IV 15 minute day 1 ; prednisone PO BID methylprednisolone IV day 1-7 ; methotrexate IT , hydrocortisone IT , cytarabine IT day 1 , 3 , 5 ; leucovorin calcium PO BID day 2 4 . Patients randomize 1 2 treatment arm . Arm III ( R-COPADM induction therapy ) : Patients receive rituximab IV day -2 ( course 1 ) 1 ; vincristine sulfate IV day 1 ; prednisone PO methylprednisolone IV day 1-5 ; high-dose methotrexate IV 4 hours* day 1 ; leucovorin calcium PO every 6 hour day 2-4 ; cyclophosphamide IV 15 minute day 2-4 ; doxorubicin hydrochloride IV day 2 ; methotrexate IT , hydrocortisone IT , cytarabine IT day 2 , 4 , 6 . Treatment repeat every 21 day 2 course . NOTE : *During second course , patient CSF-positive disease receive high-dose methotrexate IV 24 hour ( instead 4 hour ) . Consolidation therapy ( R-COPADM ) : Patients receive rituximab IV day 1 ; hydrocortisone IT methotrexate IT day 1 ; cytarabine IV 12 hour day 1-5 ; high-dose cytarabine IV 3 hour day 2-5 ; etoposide IV 2 hour day 2-5 . If CSF-positive , patient receive high-dose methotrexate IV 24 hour day 18 , methotrexate IT , hydrocortisone IT , cytarabine IT day 19 , leucovorin calcium PO every 6 hour day 19-21 . Treatment repeat every 21 day 2 course . Maintenance therapy ( R-COPADM ) : Patients receive vincristine sulfate IV day 1 ; prednisone PO methylprednisolone IV day 1-5 ; high-dose methotrexate IV 4 hour day 1 ; leucovorin calcium PO every 6 hour day 2-4 ; cyclophosphamide IV 15 minute day 2-3 ; doxorubicin hydrochloride 1 hour day 2 ; methotrexate IT , hydrocortisone IT , cytarabine IT day 2 . Beginning 28 day later , patient receive cytarabine subcutaneously ( SC ) every 12 hour day 1-5 etoposide IV 90 minute day 1-3 . Arm IV ( COPADM induction therapy ) : Patients receive vincristine sulfate , prednisone methylprednisolone , high-dose methotrexate* , leucovorin calcium , cyclophosphamide , doxorubicin hydrochloride , methotrexate , hydrocortisone , cytarabine IT arm III . NOTE : *Patients CSF-positive disease receive high-dose methotrexate IV 24 hour ( instead 4 hour ) . Consolidation therapy ( COPADM ) : Patients receive hydrocortisone methotrexate IT , cytarabine , high-dose cytarabine , etoposide arm III consolidation therapy . Maintenance therapy ( COPADM ) : Patients receive vincristine sulfate , prednisone methylprednisolone , high-dose methotrexate* , leucovorin calcium , cyclophosphamide , doxorubicin hydrochloride , methotrexate IT , hydrocortisone IT , cytarabine IT , cytarabine SC , etoposide arm III maintenance therapy . NOTE : *Patients CSF-positive disease receive high-dose methotrexate IV 24 hour . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histologically cytologically proven Bcell malignancy ; either Burkitt leukemia BAL ( = Burkitt leukemia = L3AL ) , diffuse large Bcell NHL , aggressive mature Bcell NHL non otherwise specify specifiable ( phase III ) Stage III elevate LDH level ( Bhigh ) ( LDH &gt; twice institutional upper limit adult normal value [ &gt; Nx2 ] ) , stage IV , BAL ( phase III ) Histolocytologically prove PMLBL ( phase II ) PMLBL without central nervous system ( CNS ) involvement Slides review national pathology panel , review mandatory registration Males females reproductive potential must agree use effective contraceptive method treatment , end treatment : twelve month woman , take account characteristic rituximab five month men , take account characteristic methotrexate Complete initial workup within 8 day prior treatment allow definite stag Able comply schedule followup management toxicity Signed inform consent patient and/or parent legal guardian Follicular lymphoma , MucosaAssociated Lymphoid Tissue ( MALT ) nodular marginal zone include therapeutic study In phase II study ( PMLBL ) patient CNS involvement eligible Patients congenital immunodeficiency , chromosomal breakage syndrome , prior organ transplantation , previous malignancy type , know positive human immunodeficiency virus ( HIV ) serology Evidence pregnancy lactation period There exclusion criterion base organ function Past current anticancer treatment except corticosteroid le 7 day duration total Tumor cell negative cluster differentiation ( CD ) 20 ( absence result due technical problem presence characteristic suggestive BL/DLBCL , include genetic phenotypic feature , exclusion criterion ) Prior exposure rituximab Severe active viral infection , especially hepatitis B ; severe infection ( sepsis , pneumonia , etc . ) clinically controlled time randomization ; contact national coinvestigator advice necessary Hepatitis B carrier status history hepatitis B virus ( HBV ) positive serology ; patient consider HBV carrier ( ) HBV infection case : Unimmunized hepatitis B surface antigen ( HBsAg ) and/or antiHBs antibody and/or anti HBc antibody positive , Immunized HBsAG and/or antiHBc antibody positive Important note : phase III trial , patient without known history hepatitis B could randomize study serology result available time randomization ; however , serology result positive available day 6 ( first day would due receive rituximab , randomize ) , patient must withdraw study whatever allocate treatment arm ; data center must inform immediately ; phase II trial , hepatitis B serology result must available registration ; case indicate carrier status history hepatitis B infection , patient must receive rituximab , therefore must include rituximab trial treatment arm ; case highrisk patient , recommendation treat patient standard LMB regimen correspond patient prognostic group ; case PMLBL physician leave choose appropriate therapy Participation another investigational drug clinical trial Patients , reason , able comply national legislation</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>